Senators ask why dangerous Avandia was not pulled from market

February 22nd, 2010 by Jennifer Walker-Journey

Two U.S. senators are asking the Food and Drug Administration (FDA) why the Avandia is still on the market after an agency oversight board in 2008 urged the agency to remove the GlaxoSmithKline (GSK) drug from the market because it was causing 500 additional a month. Senators Max Baucus and Charles Crassley said the major drug company even knew about the dangers of Avandia but initiated a cover up to keep the drug available to consumers.

Read the rest of this entry »

Doctors and critics doubt the accuracy of Avandia study

June 18th, 2009 by Kurt Niland

Results of a clinical study announced in New Orleans recently appeared to exonerate Avandia from long-held suspicions that the drug causes adverse cardiovascular events in patients undergoing treatment for diabetes 2. Many doctors and other critics, however, say that the study is flawed and remain unconvinced of the findings. Financial analysts believe the results will likely give GlaxoSmithKline’s one-time blockbuster drug a sales boost.

Read the rest of this entry »

Consumer watchdog urges immediate Avandia ban

November 3rd, 2008 by Kurt Niland

Consumer watchdog group Public Citizen released a petition on Thursday calling for an immediate ban on GlaxoSmithKline’s Avandia. In a petition addressed to Commissioner Dr. Von Eschenbach of the U.S. Food and Drug Administration, Public Citizen urged the ban based on trial data revealing the drug’s “multiple, serious risks.”

Read the rest of this entry »

Avandia sales drop hurting GlaxoSmithKline

October 3rd, 2008 by Kurt Niland

A UK newspaper reported yesterday that drug giant GlaxoSmithKline (GSK) – the second largest pharmaceutical company in the world – will cut 150 or more scientists and support staff positions.

Read the rest of this entry »

Type 2 diabetes drug Avandia linked to osteoporosis and bone loss

September 26th, 2008 by Scott Thomas

Researchers believe that the Avandia may cause bone loss and long-term use may speed up osteoporosis. The thinning of the bones is dangerous and could lead to fatal fractures. The study published in the December 2nd issue of Nature Medicine suggests that usage of rosiglitazone in the treatment of type II diabetes may cause osteoporosis.

Read the rest of this entry »

GSK Sent Avandia meta analysis before publication

January 31st, 2008 by Scott Thomas

GlaxoSmithKline’s Avandia is once again making the headlines after it was revealed that the peer reviewer looking at the now-notorious meta-analysis on the ’s safety profile leaked a confidential copy of the article to the firm before it was published in the New England Journal of Medicine

Read the rest of this entry »

Avandia study shows increased heart risks or death

January 8th, 2008 by Scott Thomas

Older patients who took Avandia had a higher risk of , congestive heart failure and death than those on other diabetes pills, according to a study of nearly 160,000 Canadians.

Read the rest of this entry »

Avandia a big risk to your heart

January 8th, 2008 by Scott Thomas

Montgomery, AL: Joyce A. says she did not know that Avandia could cause so many health problems, at least she did not know until her doctor took her off Avandia and put her on another drug. Unfortunately, this happened after she was hospitalized two times with severe chest pains. Although she has started to recover since being taken off Avandia, she says she still experiences some pain.

Read the rest of this entry »

Avandia starting to sound a lot like Vioxx

December 22nd, 2007 by Scott Thomas

Mark D. is fighting for justice on behalf of his brother, Grant, whose health has gone downhill since he was prescribed Avandia.

Read the rest of this entry »

Avandia heart attacks seen in general patient population

December 17th, 2007 by Scott Thomas

The consequences of deadly Avandia side-effects are now being seen in the general population, a new study has found. Previously, evidence that Avandia placed patients at an increased risk of had only been seen in clinical trials. But now, Canadian researchers have found that patients taking the controversial who are not enrolled in clinical trials are showing increased evidence of and other cardiac problems.

Read the rest of this entry »